C. Le Tourneau

625 total citations
41 papers, 399 citations indexed

About

C. Le Tourneau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, C. Le Tourneau has authored 41 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Otorhinolaryngology. Recurrent topics in C. Le Tourneau's work include Head and Neck Cancer Studies (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). C. Le Tourneau is often cited by papers focused on Head and Neck Cancer Studies (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). C. Le Tourneau collaborates with scholars based in France, United States and Switzerland. C. Le Tourneau's co-authors include Xavier Paolettí, Monia Ezzalfani, Matthew Krebs, L. Véronèse, Filippo de Braud, Justin Y. Newberg, Dexter X. Jin, Timothy R. Wilson, Ethan Sokol and David Fabrizio and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

C. Le Tourneau

36 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Le Tourneau France	12	213	142	108	72	47	41	399
Xuyang Song United States	9	331 1.6×	155 1.1×	78 0.7×	62 0.9×	39 0.8×	26	506
Patricia Tresca France	13	350 1.6×	190 1.3×	141 1.3×	127 1.8×	23 0.5×	26	542
Miah Hiang Tay Singapore	11	157 0.7×	207 1.5×	112 1.0×	76 1.1×	59 1.3×	23	437
Nathalie Syz France	5	283 1.3×	292 2.1×	62 0.6×	57 0.8×	102 2.2×	5	490
V. Papadimitrakopoulou United States	13	313 1.5×	304 2.1×	223 2.1×	110 1.5×	53 1.1×	41	606
Malek B. Hannouf Canada	11	135 0.6×	131 0.9×	29 0.3×	59 0.8×	36 0.8×	28	343
Oyewale O. Abidoye United States	13	451 2.1×	221 1.6×	143 1.3×	77 1.1×	158 3.4×	24	657
Chukwuemeka Ikpeazu United States	9	189 0.9×	144 1.0×	119 1.1×	65 0.9×	42 0.9×	23	356
Hakaru Tadokoro Brazil	10	369 1.7×	237 1.7×	83 0.8×	76 1.1×	43 0.9×	33	514
Eduardo J. Pennella United States	11	416 2.0×	377 2.7×	82 0.8×	62 0.9×	49 1.0×	33	578

Countries citing papers authored by C. Le Tourneau

Since Specialization

Citations

This map shows the geographic impact of C. Le Tourneau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Le Tourneau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Le Tourneau more than expected).

Fields of papers citing papers by C. Le Tourneau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Le Tourneau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Le Tourneau. The network helps show where C. Le Tourneau may publish in the future.

Co-authorship network of co-authors of C. Le Tourneau

This figure shows the co-authorship network connecting the top 25 collaborators of C. Le Tourneau. A scholar is included among the top collaborators of C. Le Tourneau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Le Tourneau. C. Le Tourneau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marret, Grégoire, Jerzy Klijanienko, Sophie Vacher, et al.. (2025). Internal validation strategy for high dimensional prognosis model: A simulation study and application to transcriptomic in head and neck tumors. Computational and Structural Biotechnology Journal. 27. 3792–3802. 1 indexed citations

Ferris, Robert L., Hisham Mehanna, Jonathan D. Schoenfeld, et al.. (2024). XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-risk, Cisplatin-ineligible Patients with Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN). International Journal of Radiation Oncology*Biology*Physics. 118(5). e17–e18. 1 indexed citations

Tourneau, C. Le, C. Even, Assuntina G. Sacco, et al.. (2024). 411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial. Annals of Oncology. 35. S1557–S1558. 2 indexed citations

Tourneau, C. Le, Zoltán Takácsi‐Nagy, Laetitia Finzi, et al.. (2023). Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final Results of a Phase I Trial. International Journal of Radiation Oncology*Biology*Physics. 117(2). S99–S99. 1 indexed citations

Bourhis, Jean, C. Le Tourneau, Y. Pointreau, et al.. (2022). LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study. Annals of Oncology. 33. S1400–S1400. 6 indexed citations

Tourneau, C. Le, Heinrich Becker, Rainer Claus, et al.. (2022). Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open. 7(5). 100576–100576. 11 indexed citations

Tourneau, C. Le, Valentin Calugaru, Zoltán Takácsi‐Nagy, et al.. (2021). OC-0515 NBTXR3 activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients. Radiotherapy and Oncology. 161. S399–S399.

Even, Caroline, Amaury Daste, Jérôme Fayette, et al.. (2020). 917MO TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis. Annals of Oncology. 31. S662–S662. 1 indexed citations

Tourneau, C. Le, Danny Rischin, Stefanie L. Groenland, et al.. (2020). 1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 31. S1–S1. 3 indexed citations

10.

Bourhis, Jean, C. Le Tourneau, Y. Pointreau, et al.. (2020). LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 31. S1168–S1168. 5 indexed citations

11.

Massard, Christophe, J.C. Soria, Ulrik Lassen, et al.. (2016). First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. European Journal of Cancer. 69. S15–S15. 16 indexed citations

12.

Tourneau, C. Le, Brigitte Dréno, Youlia Kirova, et al.. (2016). First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. British Journal of Cancer. 114(11). 1199–1205. 30 indexed citations

13.

Hsu, Chih‐Hung, Seung‐Hoon Lee, Samuel Ejadi, et al.. (2015). 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Annals of Oncology. 26. ix93–ix93. 13 indexed citations

14.

Paolettí, Xavier, Monia Ezzalfani, & C. Le Tourneau. (2015). Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Annals of Oncology. 26(9). 1808–1812. 45 indexed citations

15.

Tourneau, C. Le, Maud Kamal, Olivier Trédan, et al.. (2013). Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Refractory Cancer Patients: Shiva Design. Annals of Oncology. 24. i36–i36.

16.

Cacheux, Wulfran, Pascale Mariani, C. Le Tourneau, et al.. (2012). Three different KRAS statuses in three synchronous colorectal cancers. Medical Oncology. 29(4). 2864–2865.

17.

Paolettí, Xavier, Sophie Postel‐Vinay, Vincent Servois, et al.. (2010). [Dose finding methods for targeted agents: new perspectives].. PubMed. 97(12). 1485–95. 2 indexed citations

18.

Tourneau, C. Le, Eric Winquist, Sébastien J. Hotte, et al.. (2010). Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 28(15_suppl). 5531–5531. 13 indexed citations

19.

You, Benoît, et al.. (2009). 8527 A phase II trial of erlotinib after gemcitabine plus platinum-based chemotherapy in patients (pts) with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). European Journal of Cancer Supplements. 7(2). 478–479. 4 indexed citations

20.

Aussilhou, Béatrice, Sandrine Faivre, D. Lepillé, et al.. (2008). Preoperative bevacizumab may impair liver hypertrophy of the future remnant liver after a portal vein occlusion in patients undergoing major resections of colorectal liver metastasis. Journal of Clinical Oncology. 26(15_suppl). 4081–4081. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact